Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Zhejiang Cancer Hospital
Age
18–100
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
1. Voluntary participation in the clinical study: full understanding of the study, provision of written informed consent, willingness and ability to comply with all study procedures.
If bone marrow is involved: platelet ≥ 50 × 10⁹/L, ANC ≥ 1.0 × 10⁹/L, hemoglobin ≥ 8.0 g/dL.
2. Hepatic function: serum bilirubin ≤ 1.5 × upper limit of normal (ULN); aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 1.5 × ULN (≤ 5 × ULN if liver involvement).
3. Renal function: serum creatinine ≤ 1.5 × ULN.
4. Coagulation: INR ≤ 1.5 × ULN; PT and APTT ≤ 1.5 × ULN (unless on therapeutic anticoagulation with values within expected range).
10. Negative serum pregnancy test for females of childbearing potential. Effective contraception required from informed consent until 6 months after the last chemotherapy.
11. Negative ophthalmologic evaluation, including dilated fundoscopy, slit-lamp examination, and color fundus photography.
You may not be if
1. History of other malignancy within the past 5 years.
2. Burkitt lymphoma, primary central nervous system lymphoma, or B-cell lymphoma transformed from indolent lymphoma.
3. Existing brain parenchymal or meningeal lymphoma involvement.
4. Patients who have received any form of CNS prophylaxis.
5. Patients who have received whole-brain radiotherapy or craniospinal irradiation.
6. Patients with obstructive hydrocephalus requiring neurosurgical intervention.
7. Presence of any of the following known infections or conditions:
1. Active meningeal infection
2. Known human immunodeficiency virus (HIV) infection
3. Active tuberculosis
4. Active autoimmune disease
5. Interstitial lung disease or infectious pneumonia
8. Patients whose underlying conditions, in the investigator's judgment, may increase the risk associated with study drug treatment or confound the evaluation of adverse reactions.
Clareo Health | IT-TT as an Effective and Well-Tolerated Strategy for CNS Prop in High-Risk DLBCL: a Prospective Ph II Study
